Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.41 USD
-0.02 (-1.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.40 -0.01 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MRNS 1.41 -0.02(-1.06%)
Will MRNS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNS
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
MRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
Other News for MRNS
Biotech Alert: Searches spiking for these stocks today
Marinus Pharmaceuticals price target lowered by $15 at Truist, here's why
Analysts’ Top Healthcare Picks: Inspire Medical Systems (INSP), Eli Lilly & Co (LLY)
Maintaining Buy Rating on Marinus: A Balanced View on Future Prospects Despite RSE Setback
Biotech Alert: Searches spiking for these stocks today